skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

11 Total results for product and free and sample content found

HBW Insight

Sanofi's New Consumer Chief Identifies 'Untapped Potential' In Digital

By Tom Gallen 17 Nov 2020

default image

Sanofi's recently-appointed Consumer Healthcare head Julie Van Ongevalle says she has identified "untapped potential" for the business to utilize "cutting edge digital platforms." Van Ongevalle revealed her early plans for Sanofi as it reported a drop in Q3 sales.

Topic Sales Earnings Digital Health

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 17 Nov 2020

Scrip August Podcast

Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

Topic Sales Earnings

Scrip

Slow And Steady: Merck Advances COVID-19 Antiviral, Vaccine Programs

By Mandy Jackson 17 Nov 2020

Merck Covid19 antiviral

Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.

Topic Coronavirus Sales Earnings Business Strategies

Scrip

Pfizer's Bourla Urges Patience As COVID-19 Vaccine Data Timeline Lags

By Jessica Merrill 17 Nov 2020

Covid 19 Pfizer vaccine

Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.

Topic Coronavirus Vaccines Sales Earnings

Scrip

Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

By Andy Smith 29 Oct 2020

andy-smith

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air

Topic Sales Earnings Coronavirus

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 30 Jul 2020

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

Scrip

Gilead’s Major Challenge Is Sustainable Model For Remdesivir

By Joseph Haas 01 May 2020

gilead-covid

With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.

Topic Coronavirus Sales Earnings Business Strategies

Scrip

Bayer Adds Up COVID-19 Pluses and Minuses In Q1

By Kevin Grogan 30 Apr 2020

Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.

Topic Coronavirus Sales Earnings

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: